Vertex Pharmaceuticals Inc VRTX:NASDAQ

Earnings Announcement Next Earnings date is expected on 10/23/2019
Last Price$183.53NASDAQ Previous Close - Last Trade as of 2:59PM ET 10/21/19

Today's Change+7.30(4.14%)
Bid (Size)$184.90 (1)
Ask (Size)$190.70 (1)
Day Low / High$174.82 - 184.81

View Biotechnology IndustryPeer Comparison as of 10/21/2019


Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $183.53
Change: +7.30 (4.14%)
Volume: 250.00
2:59PM ET 10/21/2019

Illumina Inc ( NASDAQ )

Price: $313.83
Change: +4.39 (1.42%)
Volume: 634.7 K
3:59PM ET 10/21/2019

Biogen Inc ( NASDAQ )

Price: $223.51
Change: +3.45 (1.57%)
Volume: 2.4 M
4:00PM ET 10/21/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $297.99
Change: -2.20 (0.73%)
Volume: 539.3 K
4:00PM ET 10/21/2019

Agilent Technologies Inc ( NYSE )

Price: $75.48
Change: +0.91 (1.22%)
Volume: 1.7 M
6:30PM ET 10/21/2019

Read more news Recent News

--Vertex Pharmaceuticals Due off Trading Halt at 4:30 pm ET
4:07PM ET 10/21/2019 MT Newswires

Price: 183.98, Change: +7.75, Percent Change: +4.40 ...

Vertex Pharmaceuticals' Cystic Fibrosis Treatment Gets FDA Approval; Shares Rally 4% Before Halt
3:20PM ET 10/21/2019 MT Newswires

Shares of Vertex Pharmaceuticals (VRTX) have been halted, last up more than 4%. The FDA approved the company's Trikafta as a triple combination treatment...

Vertex Pharmaceuticals Says Cystic Fibrosis Drugs Symdeko, Orkambi Now Reimbursed in Australia
7:22AM ET 10/21/2019 MT Newswires

Biopharmaceutical company Vertex Pharmaceuticals (VRTX) said Sunday that its Symdeko and Orkambi cystic fibrosis drugs are now reimbursable in Australia. ...

Vertex Gets Positive CHMP Opinion for Expanded Label for Cystic Fibrosis Drug
11:56AM ET 10/18/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval...

View all Commentary and Analysis

Crispr Therapeutics: At The Top Of My Shopping List
11:53AM ET 10/21/2019 Seeking Alpha

Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)
7:30AM ET 9/29/2019 Seeking Alpha

Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx
8:41AM ET 9/28/2019 Seeking Alpha

Vertex Makes Substantial Strides In Diversifying Its Pipeline
4:48PM ET 9/11/2019 Seeking Alpha

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Number of Employees2,500
Recent SEC Filing10/21/20194
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$177.23
Previous Close$183.53
52 Week Range$151.80 - 195.81
Market Capitalization$47.2 B
Shares Outstanding257.0 M
SectorHealth Technology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings20.66
Earnings per Share$8.44
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin64.55%
Return on Equity51.71%

Analyst Ratings as of 10/16/2019

Consensus RecommendationConsensus Icon
Powered by Factset